Literature DB >> 19891552

Thiopurine S-methyltransferase pharmacogenetics in a large-scale healthy Italian-Caucasian population: differences in enzyme activity.

Loredana Serpe1, Pier Luigi Calvo, Elisabetta Muntoni, Sergio D'Antico, Mario Giaccone, Alessandra Avagnina, Maurizio Baldi, Cristiana Barbera, Franco Curti, Angelo Pera, Mario Eandi, Gian Paolo Zara, Roberto Canaparo.   

Abstract

AIMS: To investigate the influence of genotype, age and gender on the thiopurine S-methyltransferase (TPMT) phenotype in healthy Italian-Caucasian subjects. MATERIALS &
METHODS: The study investigated the TPMT genotype and the TPMT phenotype of 943 healthy Italian-Caucasian subjects of different age and gender (age range: 0.08-68 years; 623 males 320 females). TPMT red blood cell activity was measured in all samples and genotype was determined for the TPMT alleles *2, *3A, *3B and *3C.
RESULTS: TPMT activity levels in our whole population ranged from 1.6 up to 75.2 U/gHb. Significant TPMT activity differences between wild-type and heterozygous subjects were observed. We divided our TPMT activity into four categories according to our frequency distribution: low (0.1%), intermediate (32.9%), normal (60%) and high (7%), with arbitrary cut-off values of 8.0, 19.4 and 37.0 U/gHb, respectively. The whole population had a total of 94.5% of homozygous wild-type subjects, 5.4% heterozygous variants and one (0.1%) compound heterozygous variant TPMT*3B/*3C. The overall concordance rate between TPMT genotypes and phenotypes was 71.6%. The TPMT activity was significantly higher in wild-type children (0.08-17 years) than in wild-type adults (aged 18-68 years). Moreover, it was noted that wild-type infants from 0.08 to 5 years had a 9% higher average TPMT activity than the other wild-type groups, and only in children from 0.08 to 2 years was the TPMT activity higher in males than in females.
CONCLUSION: The data obtained in this study show that genetic factors seem to be the major aspect in TPMT phenotype variability in adults, whilst, in children, other physiological factors should be taken into consideration when assessing the TPMT phenotype, such as age and gender.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19891552     DOI: 10.2217/pgs.09.103

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  18 in total

1.  Influence of age, sex, and haplotypes of thiopurine methyltransferase (TPMT) gene on 6- mercaptopurine toxicity in children with acute lymphoblastic leukemia.

Authors:  Chakradhara Rao S Uppugunduri; Marc Ansari
Journal:  Eur J Clin Pharmacol       Date:  2011-12-14       Impact factor: 2.953

2.  Modeling the Outcome of Systematic TPMT Genotyping or Phenotyping Before Azathioprine Prescription: A Cost-Effectiveness Analysis.

Authors:  Kevin Zarca; Isabelle Durand-Zaleski; Marie-Anne Loriot; Gilles Chatellier; Nicolas Pallet
Journal:  Mol Diagn Ther       Date:  2019-06       Impact factor: 4.074

3.  Thiopurine metabolites variations during co-treatment with aminosalicylates for inflammatory bowel disease: effect of N-acetyl transferase polymorphisms.

Authors:  Gabriele Stocco; Eva Cuzzoni; Sara De Iudicibus; Diego Favretto; Noelia Malusà; Stefano Martelossi; Elena Pozzi; Paolo Lionetti; Alessandro Ventura; Giuliana Decorti
Journal:  World J Gastroenterol       Date:  2015-03-28       Impact factor: 5.742

Review 4.  Thiopurine S-methyltransferase polymorphisms and thiopurine toxicity in treatment of inflammatory bowel disease.

Authors:  Xian-Wen Dong; Qing Zheng; Ming-Ming Zhu; Jing-Lu Tong; Zhi-Hua Ran
Journal:  World J Gastroenterol       Date:  2010-07-07       Impact factor: 5.742

5.  Genomewide Approach Validates Thiopurine Methyltransferase Activity Is a Monogenic Pharmacogenomic Trait.

Authors:  C Liu; W Yang; D Pei; C Cheng; C Smith; W Landier; L Hageman; Y Chen; J J Yang; K R Crews; N Kornegay; S E Karol; F L Wong; S Jeha; J T Sandlund; R C Ribeiro; J E Rubnitz; M L Metzger; C-H Pui; W E Evans; S Bhatia; M V Relling
Journal:  Clin Pharmacol Ther       Date:  2016-11-18       Impact factor: 6.875

6.  Frequency of thiopurine S-methyltransferase mutant alleles in indigenous and admixed Guatemalan patients with acute lymphoblastic leukemia.

Authors:  Claudia Garrido; Veronica Giron Santizo; Petra Müllers; Daphney Rigaud Soriano; Giovana Bendfeldt Avila; Michael Dean; Silvia Jimenez-Morales
Journal:  Med Oncol       Date:  2013-02-03       Impact factor: 3.064

7.  Implementation of TPMT testing.

Authors:  Lynne Lennard
Journal:  Br J Clin Pharmacol       Date:  2014-04       Impact factor: 4.335

8.  Thiopurine S-methyltransferase testing for averting drug toxicity in patients receiving thiopurines: a systematic review.

Authors:  Lilla M Roy; Richard M Zur; Elizabeth Uleryk; Chris Carew; Shinya Ito; Wendy J Ungar
Journal:  Pharmacogenomics       Date:  2016-03-29       Impact factor: 2.533

Review 9.  Thiopurine S-methyltransferase testing for averting drug toxicity: a meta-analysis of diagnostic test accuracy.

Authors:  R M Zur; L M Roy; S Ito; J Beyene; C Carew; W J Ungar
Journal:  Pharmacogenomics J       Date:  2016-05-24       Impact factor: 3.550

10.  Thiopurine methyltransferase genotype-phenotype discordance and thiopurine active metabolite formation in childhood acute lymphoblastic leukaemia.

Authors:  Lynne Lennard; Cher Suzanne Cartwright; Rachel Wade; Susan M Richards; Ajay Vora
Journal:  Br J Clin Pharmacol       Date:  2013-07       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.